PubRank

Pieter A van Doorn

Author PubWeight™ 83.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008 3.59
2 A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007 2.73
3 The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005 2.39
4 Residual fatigue in Guillain-Barre syndrome is related to axonal loss. Neurology 2013 2.01
5 Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007 1.87
6 Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009 1.67
7 Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010 1.63
8 Guillain-Barré syndrome subtypes related to Campylobacter infection. J Neurol Neurosurg Psychiatry 2011 1.62
9 Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2013 1.57
10 TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain 2007 1.55
11 Revised normative values for grip strength with the Jamar dynamometer. J Peripher Nerv Syst 2011 1.48
12 Increased aortic stiffness and blood pressure in non-classic Pompe disease. J Inherit Metab Dis 2014 1.44
13 Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014 1.40
14 Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve 2003 1.32
15 High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010 1.32
16 Fatigue: an important feature of late-onset Pompe disease. J Neurol 2007 1.31
17 Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012 1.20
18 Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 2012 1.19
19 Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012 1.17
20 Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010 1.16
21 Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 2005 1.15
22 TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J Immunol 2010 1.14
23 Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain 2011 1.13
24 Does a carpal tunnel syndrome predict an underlying disease? J Neurol Neurosurg Psychiatry 2006 1.06
25 Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005 1.06
26 Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013 1.04
27 Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 2012 1.03
28 Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011 1.00
29 Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002 0.99
30 IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins. J Proteome Res 2014 0.98
31 Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010 0.96
32 Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013 0.93
33 Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress. J Clin Epidemiol 2004 0.92
34 The CMAP scan as a tool to monitor disease progression in ALS and PMA. Amyotroph Lateral Scler Frontotemporal Degener 2012 0.90
35 Increased aortic stiffness in glycogenosis type 2 (Pompe's disease). Int J Cardiol 2006 0.90
36 First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. Mol Genet Metab 2011 0.90
37 Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol 2008 0.89
38 Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 2010 0.89
39 Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. J Neuroimmunol 2004 0.88
40 Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol 2006 0.87
41 Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Ann Neurol 2003 0.87
42 Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010 0.86
43 Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients. Ann Neurol 2003 0.86
44 Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol 2007 0.85
45 Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. J Neuroimmunol 2005 0.85
46 Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. J Neurol 2011 0.83
47 Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab 2013 0.82
48 Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 2009 0.82
49 Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: correlation with pain and recovery. Pain 2011 0.82
50 The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis 2011 0.82
51 Emerging drugs for Guillain-Barré syndrome. Expert Opin Emerg Drugs 2011 0.82
52 Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis 2013 0.81
53 Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Rehabil Med 2007 0.81
54 Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Arch Neurol 2009 0.81
55 Mortality in Guillain-Barre syndrome. Neurology 2013 0.81
56 Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol 2007 0.81
57 Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome. J Peripher Nerv Syst 2009 0.81
58 ANO5 mutations in the Dutch limb girdle muscular dystrophy population. Neuromuscul Disord 2013 0.81
59 Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010 0.80
60 Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009 0.80
61 AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands. J Neurol 2009 0.79
62 Hearing in adults with Pompe disease. J Inherit Metab Dis 2011 0.79
63 Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms. J Neuroimmunol 2008 0.78
64 Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 2009 0.78
65 Host factors determine anti-GM1 response following oral challenge of chickens with Guillain-Barré syndrome derived Campylobacter jejuni strain GB11. PLoS One 2010 0.77
66 Selective digestive tract decontamination decreases time on ventilator in Guillain-Barré syndrome. Neurocrit Care 2011 0.77
67 Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome. J Neuroimmunol 2005 0.77
68 Congenital hypomyelinating neuropathy, a long term follow-up study in an affected family. Neuromuscul Disord 2007 0.76
69 Screening for antecedent Campylobacter jejuni infections and anti-ganglioside antibodies in idiopathic neuralgic amyotrophy. J Peripher Nerv Syst 2011 0.76
70 Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J Peripher Nerv Syst 2009 0.76
71 Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2010 0.76
72 Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neurosci Lett 2003 0.76
73 Pain accompanies pure motor Guillain-Barré syndrome. J Peripher Nerv Syst 2008 0.75
74 Presence or absence of cytomegalovirus in cerebrospinal fluid from patients with Guillain-Barré syndrome? J Infect Dis 2006 0.75
75 Multifocal motor neuropathy with abrupt onset and spontaneous recovery. J Neurol 2007 0.75
76 Determination of pain and response to methylprednisolone in Guillain-Barré syndrome. J Neurol 2007 0.75
77 Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitude. Neurology 2004 0.75
78 Predicting the course of Guillain-Barré syndrome. Lancet Neurol 2006 0.75
79 Diagnostic value of anti-GQ1b antibodies in a patient with relapsing dysarthria and ataxia. BMJ Case Rep 2009 0.75
80 A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers. Neuromuscul Disord 2010 0.75
81 Symptoms of activity-induced weakness in peripheral nervous system disorders. J Peripher Nerv Syst 2011 0.75
82 Transient hypertrichosis in a patient with Guillain-Barré syndrome. J Peripher Nerv Syst 2007 0.75
83 Conduction velocity distribution in neurologically well-recovered but fatigued Guillain-Barré syndrome patients. Muscle Nerve 2006 0.75
84 Health-related quality of life in Guillain-Barré syndrome patients: a systematic review. J Peripher Nerv Syst 2014 0.75
85 [A woman with polyneuropathy and white nails]. Ned Tijdschr Geneeskd 2014 0.75
86 Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016 0.75
87 Limb motor nerve dysfunction in Miller Fisher syndrome. J Peripher Nerv Syst 2013 0.75
88 Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease. Mol Genet Metab 2012 0.75
89 Concurrent myopathy in patients with Graves' orbitopathy. Orbit 2009 0.75
90 Individual patients who experienced both Guillain-Barré syndrome and CIDP. J Peripher Nerv Syst 2009 0.75
91 Multiplet discharges after electrical stimulation: new evidence for distal excitability changes in motor neuron disease. Amyotroph Lateral Scler 2012 0.75
92 Interventions for fatigue in peripheral neuropathy. Cochrane Database Syst Rev 2014 0.75